This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Mesothelioma Experts To Meet For 3rd International Symposium On Lung-Sparing Therapies For Malignant Pleural Mesothelioma May 18th

LOS ANGELES, March 18, 2013 /PRNewswire/ -- Mesothelioma experts will gather on Saturday, May 18 th 2013 for the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma at the Sheraton Delfina in Santa Monica, CA.  Dr. Robert B. Cameron, M.D., Director of the UCLA Mesothelioma Comprehensive Research Program, Chief of Thoracic Surgery at the West Los Angeles VA Medical Center and Scientific Advisor at Pacific Meso Center ( http://pacificmesocenter.org/), will again lead this year's symposium. Dr. Cameron has been a leading proponent of lung-sparing pleurectomy/decortication (P/D) surgical procedures for malignant pleural mesothelioma for nearly 20 years.

This year's meeting will include distinguished faculty and experts from prestigious universities such as UCLA, University of Pennsylvania, University of Pittsburgh, National Institutes of Health and Centro di Riferimento Oncologico CRO-Aviano in Italy.  While the seminar is primarily designed for physicians and offers continuing medical education (CME) credit, it's also open to physicians in training, nurses, mesothelioma victims, their families, students, and other interested parties.

At the 1st and 2nd annual International Symposia, specialists concluded that if surgical treatment was to be performed at all, the preferred treatment is the pleurectomy decortication (P/D) over the more radical extra-pleural pneumonectomy (EPP) surgery. P/D is an operation for mesothelioma that removes the involved pleura and frees the underlying lung so that it can expand and fill the pleural cavity, whereas EPP surgery involves the removal of the lung along with its coverings and the associated coverings of the heart, diaphragm and pericardium.

"Once again, this symposium highlights the best research and thinking by bringing the preeminent scientific and medical minds from around the world that are advancing the treatment of mesothelioma," said Dr. Cameron. "Research and practice over the past several years have continued to evolve working to improve cancer outcomes without unnecessarily sacrificing the affected lung. Clearly, it is best for the patient to treat mesothelioma as a chronic illness while preserving the function of both lungs," he added.

The Worthington Caron Law Firm ( http://www.rogerworthington.com/) is once again sponsoring the symposium for $50,000 as a Platinum sponsor. Gold sponsors at $15,000 are Napoli Bern ( http://www.napolibern.com/) and Simons Greenstone Panatier and Bartlett ( http://www.sgpblaw.com/). "The generosity of our sponsors enables us to continue to provide the most up-to-date information on treatment and therapies to the medical community. The information allows mesothelioma sufferers and their family members to make sound decisions as to their best treatment options," said Clare Cameron, Executive Director of PMC. 

Early Bird tickets can be purchased before May 3 rd online at www.cme.ucla.edu/courses.

For more information, please contact UCLA at 310-794-2620 or call Clare Cameron at the Pacific Meso Center at Pacific Heart, Lung, Blood Institute at 310-478-4678.

http://www.pacificmesocenter.org  

Contact: Clare Cameron310-478-4678

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE The Pacific Meso Center

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,974.31 -31.44 -0.18%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,549.2260 -15.0680 -0.33%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs